Security key
36254L308
- Security type / class
- Equity / Common Stock
- Total 13F shares
- 99,688
- Total 13F value
- $220,497
- Share change
- -1,145,192
- SEC-reported price per share
- $2.15
- Number of holders
- 20
- Value change
- -$29,000,935
- Number of buys
- 5
- Number of sells
- 6
- Shares outstanding
- 3,148,458
Holder snapshot
6 signals
Security identity
Names, identifiers, and filing context for this profile.
1 source field
Report period
Q1 2025
Institutions
20
Top holders
10
GTBP full security history
Ownership snapshot
Full 13F holder table
Newer quarter: Q3 2025
GT Biopharma, Inc. SEC filings
GT Biopharma, Inc. company facts
Broader feeds
Reporting periods
Holder history for CUSIP 36254L308
Recent filing periods:
Ownership snapshot
Top reported holders of GTBP - GT Biopharma, Inc. - Common Stock (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
CYTOVANCE BIOLOGICS INC
Disclosed value leader
Deutsche Girozentrale Dek...
Comparable rows
15/15
Latest evidence
31 Dec 2024
13D/G
13F
Lead comparable stake: 9.8%
13D/G row: CYTOVANCE BIOLOGICS INC
Showing 1-6 of 15 holder rows.
Quick read
CYTOVANCE BIOLOGICS INC leads the comparable SEC ownership view at 9.8%.
15 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens CYTOVANCE BIOLOGICS INC's linked filing trail.
Comparable ownership
Top 5
CYTOVANCE BIOLOGICS INC
9.8%
Deutsche Girozentrale DekaBank
37%
BANK OF MONTREAL /CAN/
0.92%
GEODE CAPITAL MANAGEMENT, LLC
0.47%
VANGUARD GROUP INC
0.33%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-6 of 15 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| CYTOVANCE BIOLOGICS INC |
13D/G
|
9.8%
|
$478,416
219,457 shares
|
$0 | 30 Sep 2024 |
| Deutsche Girozentrale DekaBank |
13F
Individual
|
37%
|
$29,023,000
1,154,867 shares
|
— | 31 Dec 2024 |
| BANK OF MONTREAL /CAN/ |
13F
Company
|
0.92%
|
$88,301
28,951 shares
|
— | 31 Dec 2024 |
| GEODE CAPITAL MANAGEMENT, LLC |
13F
Company
|
0.47%
|
$45,457
14,899 shares
|
— | 31 Dec 2024 |
| VANGUARD GROUP INC |
13F
Company
|
0.33%
|
$32,037
10,504 shares
|
— | 31 Dec 2024 |
| WELLS FARGO & COMPANY/MN |
13F
Company
|
0.32%
|
$30,540
10,013 shares
|
— | 31 Dec 2024 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
13F holder rows
Institutional holders as of Q1 2025
Investor-level positions for this CUSIP, loaded as an interactive table.
Institutions
20
Shares
99,688
Rows available
20
| Investor | Option | Weight % | Change % | SEC-reported value | * Price | Shares | Share Change | Activity | Report Period |
|---|
* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.
Compare Q1 2025 vs Q1 2026 Across Filers
Q1 2026 holders
39
Q1 2025 holders
20
Holder diff
-19
| Investor | Q1 2026 Shares | Q1 2025 Shares | Share Diff | Share Chg % | Q1 2026 value | Q1 2025 value | Value change | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend